How are ValiRx developing personalised medicines for the treatment of cancer?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How are ValiRx developing personalised medicines for the treatment of cancer?
Released on: September 24, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    If you experience problems with the audio on this interview please use mp4 link.
  • Summary
  • Transcript
  • Participants
  • Company
If you experience problems with the audio on this interview please use mp4 link.
bit.ly/1wQTjzx

Overzealous, rebellious or inappropriate activity by specific genes contributes to many diseases states including cancers, inflammatory conditions, Alzheimer’s and autoimmune diseases. During NLSD 2014 in Stockholm, George Morris, COO of ValiRx explains to Fintan Walton how ValiRx’s proprietary GeneICE technology enables selective silencing of the rebellion, preventing activity from the rebellious gene.
Overzealous, rebellious or inappropriate activity by specific genes contributes to many diseases states including cancers, inflammatory conditions, Alzheimer’s and autoimmune diseases. During NLSD 2014 in Stockholm, George Morris, COO of ValiRx explains to Fintan Walton how ValiRx’s proprietary GeneICE technology enables selective silencing of the rebellion, preventing activity from the rebellious gene. He also give an update on where they are with their lead products in prostate cancer and lung cancer.
George Morris
ValiRx
George has over 25 years’ experience in biological and medical research, and financial services. In the past he has worked for Guy‘s hospital medical school department of medicine, King’s college and University College London. As a Research Scientist, he is an author of numerous books and articles on refereed papers, approximately 70 abstracts, short reports and posters, and an inventor of multiple patents.

George was a founding member of the expert advisory panel, the ‘Biotechnology and Finance Forum’, set up jointly between the European Commission and the European Association of Securities Dealers. George involved in a number of conferences and workshops with the EU research and agricultural directorates and is an ‘expert’ to the Commission, and has been invited into several policy discussion groups.

George has worked with a variety of commercial, governmental organisations and financial institutions in the US, Europe and Australia and many consultancy projects covering various biotechnology and financial activities. He is regularly asked to chair or participate in conferences in his areas of experience, including acting as a ‘Venture Academy’ mentor. Has undertaken numerous continuing professional development courses covering finance and general management as well as in specific areas related to science & technology, statistics.
ValiRx plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.